"Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808)

E. Engelsman, J. C M Klijn, R. D. Rubens, J. Wildiers, L. V A M Beex, M. A. Nooij, N. Rotmensz, R. Sylvester

Research output: Contribution to journalArticle

Abstract

The "classical" CMF (cyclophosphamide/methotrexate/5-fluorouracil) schedule was compared with a modified 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer, as concern had arisen as to whether the classical schedule was the optimal way to give these drugs. The response rate with classical CMF was 48% compared with 29% for intravenous CMF (P = 0.003). Response duration was similar at 11 months, but survival longer for the classical schedule (17 versus 12 months, P = 0.016). We conclude that classical CMF is the superior regimen and attribute this to the higher dose intensity achieved.

Original languageEnglish
Pages (from-to)966-970
Number of pages5
JournalEuropean Journal of Cancer and Clinical Oncology
Volume27
Issue number8
DOIs
Publication statusPublished - 1991

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of '"Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808)'. Together they form a unique fingerprint.

  • Cite this